COMP <GO>
TMCI vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
Treace Medical Concepts Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: TMCI 1
— JNJ 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: JNJ
LAST: $5.06 (+4.76%) • MKT CAP: $329.1M
balance-sheet
0.90
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TMCI VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TMCI | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.80% | 67.90% | +11.90 | TMCI | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.40% | 25.50% | -57.90 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.96% | 2.97% | -11.93 | JNJ | /fcf-yield <GO> |
| Operating Margin | -25.50% | 34.70% | -60.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -27.70% | 28.50% | -56.20 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 1.60% | 6.00% | -4.40 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 0.90 | 5.59 | -4.69 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.6 | 62.1 | -10.49 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $329.1M | $662.49B | -$662.16B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TMCI REV | JNJ REV | TMCI GROSS % | JNJ GROSS % | TMCI FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $212.7M | $94.19B | 79.8% | 67.9% | -$29.5M | $19.70B |
| FY 2024 | $209.4M | $88.82B | 80.4% | 69.1% | -$48.8M | $19.84B |
| FY 2023 | $187.1M | $85.16B | — | — | -$34.6M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TMCI // BETA —
JNJ // BETA 1.08